Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide and Alemtuzumab in CD52+ Aggressive Lymphomas
NCT03132584Phase 1Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2017
- Primary completion
- Jan 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alemtuzumab in non-Hodgkin lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) and lymphoproliferative disorder (LPD), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Maximum Tolerated Dose of Cyclophosphamide and Alemtuzumab at 28 days. Started Jul 2017; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
non-Hodgkin lymphoma (NHL)diffuse large B-cell lymphoma (DLBCL)lymphoproliferative disorder (LPD)
Beyond the preview
Go deeper on NCT03132584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03132584.